WO2004091476A3 - 心臓疾患治療物質のスクリーニング方法および心臓疾患治療医薬組成物 - Google Patents

心臓疾患治療物質のスクリーニング方法および心臓疾患治療医薬組成物 Download PDF

Info

Publication number
WO2004091476A3
WO2004091476A3 PCT/JP2004/005382 JP2004005382W WO2004091476A3 WO 2004091476 A3 WO2004091476 A3 WO 2004091476A3 JP 2004005382 W JP2004005382 W JP 2004005382W WO 2004091476 A3 WO2004091476 A3 WO 2004091476A3
Authority
WO
WIPO (PCT)
Prior art keywords
heart disease
treating
autoantibody
medicinal composition
myocardial troponin
Prior art date
Application number
PCT/JP2004/005382
Other languages
English (en)
French (fr)
Other versions
WO2004091476A1 (ja
WO2004091476A2 (ja
Inventor
Tasuku Honjo
Taku Okazaki
Original Assignee
Ono Pharmaceutical Co
Tasuku Honjo
Taku Okazaki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co, Tasuku Honjo, Taku Okazaki filed Critical Ono Pharmaceutical Co
Priority to AT04727715T priority Critical patent/ATE494549T1/de
Priority to DE602004030898T priority patent/DE602004030898D1/de
Priority to US10/553,406 priority patent/US7407767B2/en
Priority to EP04727715A priority patent/EP1619498B1/en
Priority to JP2005505446A priority patent/JP4545685B2/ja
Publication of WO2004091476A1 publication Critical patent/WO2004091476A1/ja
Publication of WO2004091476A2 publication Critical patent/WO2004091476A2/ja
Publication of WO2004091476A3 publication Critical patent/WO2004091476A3/ja

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rehabilitation Therapy (AREA)
  • Hospice & Palliative Care (AREA)
PCT/JP2004/005382 2003-04-16 2004-04-15 心臓疾患治療物質のスクリーニング方法および心臓疾患治療医薬組成物 WO2004091476A2 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AT04727715T ATE494549T1 (de) 2003-04-16 2004-04-15 Screening-verfahren für heilmittel gegen herzkrankheit und medizinische zusammensetzung zur behandlung von herzkrankheit
DE602004030898T DE602004030898D1 (de) 2003-04-16 2004-04-15 Screening-verfahren für heilmittel gegen herzkrankheit und medizinische zusammensetzung zur behandlung von herzkrankheit
US10/553,406 US7407767B2 (en) 2003-04-16 2004-04-15 Method of screening remedy for heart disease and medicinal composition for treating heart disease
EP04727715A EP1619498B1 (en) 2003-04-16 2004-04-15 Method of screening remedy for heart disease and medicinal composition for treating heart disease
JP2005505446A JP4545685B2 (ja) 2003-04-16 2004-04-15 心臓疾患治療物質のスクリーニング方法および心臓疾患治療医薬組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003111703 2003-04-16
JP2003-111703 2003-04-16

Publications (3)

Publication Number Publication Date
WO2004091476A1 WO2004091476A1 (ja) 2004-10-28
WO2004091476A2 WO2004091476A2 (ja) 2004-10-28
WO2004091476A3 true WO2004091476A3 (ja) 2005-03-03

Family

ID=33296005

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/005382 WO2004091476A2 (ja) 2003-04-16 2004-04-15 心臓疾患治療物質のスクリーニング方法および心臓疾患治療医薬組成物

Country Status (6)

Country Link
US (1) US7407767B2 (ja)
EP (1) EP1619498B1 (ja)
JP (1) JP4545685B2 (ja)
AT (1) ATE494549T1 (ja)
DE (1) DE602004030898D1 (ja)
WO (1) WO2004091476A2 (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070172888A1 (en) * 2006-01-25 2007-07-26 Klaus Hallermayer Measuring troponin antibodies to assess cardiovascular risk
WO2008051762A2 (en) * 2006-10-26 2008-05-02 Abbott Laboratories Immunoassay of analytes in samples containing endogenous anti-analyte antibodies
US7776605B2 (en) 2006-10-26 2010-08-17 Abbott Laboratories Assay for cardiac troponin autoantibodies
US20080305512A1 (en) * 2006-10-26 2008-12-11 Mattingly Phillip G Assay for cardiac troponin autoantibodies
EP2115466A4 (en) * 2006-12-22 2010-07-28 Abbott Lab HEART CIRCUIT AUTOIMMUNE DISEASE TEST GROUP AND METHOD FOR USE THEREOF
US7601689B2 (en) * 2007-04-12 2009-10-13 Naidu Lp Angiogenin complexes (ANGex) and uses thereof
US8420330B2 (en) 2011-07-15 2013-04-16 Myra A. Lipes Diagnosis and treatment of cardiac troponin 1 (cTn1) autoantibody-mediated heart disease
CA2800460A1 (en) * 2009-04-28 2010-11-11 Innovative Laboratory Technologies, Inc. Lateral-flow immuno-chromatographic assay devices
US20110136141A1 (en) * 2009-12-03 2011-06-09 Abbott Laboratories Peptide reagents and method for inhibiting autoantibody antigen binding
WO2011156740A2 (en) * 2010-06-10 2011-12-15 Myra Lipes Diagnosis of myocardial autoimmunity in heart disease
US20130121998A1 (en) * 2010-06-16 2013-05-16 Myra A. Lipes Diagnosis of Myocardial Autoimmunity in Heart Disease
CN112691193B (zh) * 2021-01-08 2022-06-24 华中科技大学同济医学院附属同济医院 用于治疗扩张型心肌病的药物及筛选方法及用途
US20240082189A1 (en) * 2021-01-25 2024-03-14 Juntendo Educational Foundation Therapeutic agent for hypertrophic cardiomyopathy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09503050A (ja) * 1993-05-17 1997-03-25 フォートロン バイオサイエンス インク． 心臓トロポニン▲ｉ▼のアッセイ
JPH10512672A (ja) * 1995-01-19 1998-12-02 パストゥール・サノフィ・ディアグノスティク 心臓トロポニンｉの超高感度アッセイ法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4637880A (en) * 1981-11-30 1987-01-20 Cordis Laboratories, Inc. Apparatus and method for therapeutic immunodepletion
US7119248B1 (en) * 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
US5534615A (en) * 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
AU3483395A (en) 1994-09-28 1996-04-19 Spectral Diagnostics Inc. A monoclonal antibody to human cardiac troponin i
US5795725A (en) * 1995-04-18 1998-08-18 Biosite Diagnostics Incorporated Methods for the assay of troponin I and T and selection of antibodies for use in immunoassays
WO1999011814A1 (en) * 1997-09-04 1999-03-11 Board Of Trustees Of Leland Stanford Jr. University Assays for detecting modulators of cytoskeletal function
AU6117099A (en) 1998-10-21 2000-05-08 Spectral Diagnostics Inc. Cardiac troponin i polypeptide fragments and uses in diagnostics
US6495376B1 (en) * 1999-02-18 2002-12-17 Beth Israel Deaconess Medical Center Methods and compositions for regulating protein-protein interactions
WO2000054770A1 (en) 1999-03-15 2000-09-21 Boston Life Sciences, Inc. Pharmaceutical compositions comprising troponin subunits, fragments and homologs thereof and methods of their use to inhibit angiogenesis
US7064180B2 (en) * 2000-07-31 2006-06-20 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
KR20030066657A (ko) 2000-11-15 2003-08-09 오노 야꾸힝 고교 가부시키가이샤 Ｐｄ-1 결손 마우스 및 그 용도
CA2446723C (en) * 2001-05-25 2014-01-21 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
EP1412479A4 (en) 2001-07-12 2004-07-28 Geron Corp CELLS WITH CARDIOMYOCYTE GENERATION PRODUCED FROM HUMAN PLURIPOTENT STEM CELLS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09503050A (ja) * 1993-05-17 1997-03-25 フォートロン バイオサイエンス インク． 心臓トロポニン▲ｉ▼のアッセイ
JPH10512672A (ja) * 1995-01-19 1998-12-02 パストゥール・サノフィ・ディアグノスティク 心臓トロポニンｉの超高感度アッセイ法

Also Published As

Publication number Publication date
JPWO2004091476A1 (ja) 2006-07-06
EP1619498A4 (en) 2006-06-14
EP1619498B1 (en) 2011-01-05
US20060246525A1 (en) 2006-11-02
EP1619498A2 (en) 2006-01-25
DE602004030898D1 (de) 2011-02-17
ATE494549T1 (de) 2011-01-15
JP4545685B2 (ja) 2010-09-15
US7407767B2 (en) 2008-08-05
WO2004091476A2 (ja) 2004-10-28

Similar Documents

Publication Publication Date Title
WO2004091476A3 (ja) 心臓疾患治療物質のスクリーニング方法および心臓疾患治療医薬組成物
WO2004091476A1 (ja) 心臓疾患治療物質のスクリーニング方法および心臓疾患治療医薬組成物
McNally et al. Opioid receptors in the midbrain periaqueductal gray regulate extinction of pavlovian fear conditioning
Liu et al. Suppression of autophagy by FIP200 deletion leads to osteopenia in mice through the inhibition of osteoblast terminal differentiation
Sanders et al. Interstitial cells of Cajal as pacemakers in the gastrointestinal tract
Wojtowicz et al. The effects of running and of inhibiting adult neurogenesis on learning and memory in rats
Weinberger et al. Learning-induced physiological memory in adult primary auditory cortex: receptive field plasticity, model, and mechanisms
WO2005050200A3 (en) Screening assays and methods of tumor treatment
EA201000245A1 (ru) Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf
Harris et al. Augmented accumbal serotonin levels decrease the preference for a morphine associated environment during withdrawal
EP2306192A3 (en) Risk Markers For Cardiovascular Disease
WO2000001350A3 (de) Material zur modifizierung der optischen eigenschaften unterschiedlicher zellen, gerät zum applizieren dieses materiales, diagnosegärat zum bestimmen der optischen eigenschaften von zellen, sowie gerät zum bestrahlen von zellen
DE69900816T2 (de) Modifizierter ciliary neurotrophic factor (cntf), und verfahren zu dessen herstellung und verwendung
Wang et al. Accelerated chondrogenesis of the rabbit cranial base growth plate by oscillatory mechanical stimuli
IL142824A0 (en) Lipoic acid derivatives and their use in treatment of disease
BRPI0309665B8 (pt) método para analisar uma preparação de alfagalactosidase a
WO2004006854A3 (en) Method for identification of biologically active agents
Bonaventura et al. Target deconvolution studies of (2R, 6R)-hydroxynorketamine: an elusive search
Khalil et al. Compliance to the prescribed dose and overall treatment time in five randomized clinical trials of altered fractionation in radiotherapy for head-and-neck carcinomas
Maratta et al. Distribution and density of contacts from noradrenergic and serotonergic boutons on the dendrites of neck flexor motoneurons in the adult cat
Martin et al. Growth, modeling and remodeling of bone
Gardner et al. Electrically stimulated hind limb muscle contractions increase adult hippocampal astrogliogenesis but not neurogenesis or behavioral performance in male C57BL/6J mice
Grant et al. Update on pathological gambling
Thorpe et al. Alterations in time–place learning induced by lesions to the rat medial prefrontal cortex
SE0002189D0 (sv) New method and assay

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005505446

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2006246525

Country of ref document: US

Ref document number: 10553406

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004727715

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004727715

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10553406

Country of ref document: US